| AMR | Antimicrobial Resistance |
| HRDR | Host Range Determinant Region |
| ACR | Anti-CRISPR |
| MRSA | Methicillin-Resistant Staphylococcus aureus |
| PEG | Polyethylene Glycol |
| MDR | Multidrug-Resistant |
| XDR | Extensively Drug-Resistant |
| EPEs | Engineered Phage Enzymes |
| IBD | Inflammatory Bowel Disease |
| CRC | Colorectal Cancer |
| NAFLD | Non-Alcoholic Fatty Liver Disease |
| NE | Neutrophil Elastase |
| CRKP | Carbapenem-Resistant Klebsiella pneumoniae |
| TME | Tumor Microenvironment |
| UC | Ulcerative Colitis |
| DIO | Diet-Induced Obesity |
| BCa | Breast Cancer |
| GMP | Good Manufacturing Practice |
| eIND | emergency Investigational New Drug |
| PK | Pharmacokinetic |
| PD | Pharmacodynamic |
| RCTs | Randomized Controlled Trials |